Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.

A new targeted treatment for a rare and aggressive bile duct cancer has been approved by NICE, offering patients the chance of longer survival and

Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according to data presented late on Tuesday. The

The Centers for Medicare and Medicaid Services has delayed a key pilot program focused on Medicare coverage for obesity medications, after insurance plans indicated they